Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 juin 2021 09h00 HE | Source: CohBar, Inc.

CohBar to Present at the BIO 2021 Digital Conference

MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
17 mai 2021 16h02 HE | Source: CohBar, Inc.

CohBar Reports First Quarter 2021 Financial Results and Provides Business Update

MENLO PARK, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
03 mai 2021 09h00 HE | Source: CohBar, Inc.

CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021

MENLO PARK, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
27 avr. 2021 08h30 HE | Source: CohBar, Inc.

CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director

MENLO PARK, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
21 avr. 2021 09h00 HE | Source: CohBar, Inc.

CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

MENLO PARK, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
14 avr. 2021 09h00 HE | Source: CohBar, Inc.

CohBar to Present at the Mitochondria-Targeted Drug Development Summit

MENLO PARK, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
30 mars 2021 16h02 HE | Source: CohBar, Inc.

CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update

MENLO PARK, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
29 mars 2021 09h00 HE | Source: CohBar, Inc.

CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

MENLO PARK, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
16 mars 2021 16h05 HE | Source: CohBar, Inc.

CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021

MENLO PARK, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
16 mars 2021 09h00 HE | Source: CohBar, Inc.

CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases

MENLO PARK, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...

Page précédente

Page suivante